Bill is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC). He is a medical oncologist who specializes in the treatment of patients with soft tissue and bone sarcomas. His research efforts are directly related to the clinical needs of patients with this rare and heterogeneous group of malignancies. He is interested in understanding the genetic and molecular nuances of sarcoma with an emphasis on identifying and validating novel therapeutic targets and treatment biomarkers and modeling drug resistance. Bill has been very successful in translating basic science by designing collaborative research programs and clinical trials with extensive correlates at all phases of development. He is the MSKCC Principal Investigator for the UM1 Atlantic Coast Phase 2 Consortium (NCI 3UM1CA186691-03S1-ETCTN) and a project and core facility leader in the MSKCC SPORE in Soft Tissue Sarcoma (NIH/NCI 1P50CA217694-01A1). His SPORE project utilizes liposarcoma as a model for defining the cellular mechanisms of geroconversion and drug induced senescence with CDK4/6 inhibitors. Bill received his Medical Degree from Jefferson Medical College in Philadelphia, PA and performed his residency in Internal Medicine at the Vanderbilt University Medical Center in Nashville, TN and his fellowship in Hematology and Medical Oncology at the UCLA Medical Center in Los Angeles, CA. Bill also has a tremendous interest Adolescent and Young Adult (AYA) cancer care and in affecting disparities and promoting equity in healthcare as well as global healthcare initiatives in underserved areas. Bill is currently developing an AYA Program at MSKCC and has recently served as the Chair of the American Society of Clinical Oncology’s Health Equity Committee and the Chair for the Oncology Committee at Health Volunteers Overseas.
William Douglas Tap, MD